ZHONGZHIPHARM (03737) announced its financial results for the six months ended June 30, 2025, reporting revenue of RMB 880 million, representing a year-on-year decrease of 19.1%. Profit attributable to owners of the parent company reached RMB 8.783 million, marking a significant decline of 89.5% compared to the same period last year. Basic earnings per share stood at RMB 0.010.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.